

# **Endovascular Management of Medically Refractory Intracranial Arterial Stenosis**

**Thesis**

*Submitted for Partial Fulfillment of MD Degree  
in Neurology*

**By**

**Romany Adly Yousef**

*M.B.B.Ch. M.Sc., Neuropsychiatry*

**Under Supervision of**

**Prof. Dr. Ayman Mohamed Nassef**

*Professor of Neurology*

*Faculty of Medicine- Ain Shams University*

**Prof. Dr. Eman Mahmoud Awad**

*Professor of Neurology*

*Faculty of Medicine - Ain Shams University*

**Dr. Ahmed Ali El-bassiouny**

*Assistant Professor of Neurology*

*Faculty of Medicine - Ain Shams University*

**Dr. Hossam Eldin Mahmoud Afify**

*Lecturer of Neurology*

*Faculty of Medicine - Ain Shams University*

**Dr. Mohamed Ahmed Shafik**

*Lecturer of Neurology*

*Faculty of Medicine - Ain Shams University*

**Faculty of Medicine**

**Ain Shams University**

**2019**



## Acknowledgement

No words can express my deepest appreciation and profound respect to **Prof. Dr. Ayman Mohamed Nassef**, Professor of Neurology, Ain Shams University, for his continuous guidance and support. He has generously devoted much of his time and his effort for planning and supervision of this study.

Also, my profound gratitude to **Prof. Dr. Eman Mahmoud Awad**, Professor of Neurology, Ain Shams University, for her kind supervision and support. It was a great honor to work under her supervision.

I would like also to thank **Dr. Ahmed Ali El-bassiouny**, Assistant Professor of Neurology, Ain Shams University, for his support, help and constructive criticism during this work.

I would like also to thank **Dr. Hossam Eldin Mahmoud Afify**, Lecturer of Neurology, Ain Shams University, for his support and help during this work.

Also, my profound gratitude to **Dr. Mohamed Ahmed Shafik**, Lecturer of Neurology, Ain Shams University, for his great care and support.

Last but not least, I wish to express my love and respect to **my lovely wife, my son and my family**, for their endless love and care, for their valuable emotional support and continuous encouragement which brought the best out of me. I owe them all every achievement throughout my life.

Finally, my thanks should go to all **the patients** who were the subjects of this work and who cooperated in this research.

**Romany Adly Yousef**



# List of Contents

| <b>Subject</b>                                              | <b>Page No.</b> |
|-------------------------------------------------------------|-----------------|
| <b>List of Abbreviations .....</b>                          | <b>I</b>        |
| <b>List of Figures.....</b>                                 | <b>III</b>      |
| <b>List of Tables .....</b>                                 | <b>IV</b>       |
| <b>Introduction.....</b>                                    | <b>1</b>        |
| <b>Aim of the Work.....</b>                                 | <b>6</b>        |
| <b>Review of Literature</b>                                 |                 |
| <b>Chapter (1): Pathophysiology of Ischemic Stroke.....</b> | <b>7</b>        |
| <b>Chapter (2): Intracranial Arterial Stenosis .....</b>    | <b>24</b>       |
| <b>Chapter (3): Management of Intracranial</b>              |                 |
| <b>Stenosis .....</b>                                       | <b>42</b>       |
| <b>Subjects and Methods.....</b>                            | <b>71</b>       |
| <b>Results .....</b>                                        | <b>83</b>       |
| <b>Discussion.....</b>                                      | <b>125</b>      |
| <b>Conclusion .....</b>                                     | <b>137</b>      |
| <b>Recommendations.....</b>                                 | <b>138</b>      |
| <b>Summary.....</b>                                         | <b>139</b>      |
| <b>References.....</b>                                      | <b>141</b>      |
| <b>Appendices.....</b>                                      | <b>165</b>      |
| <b>Arabic Summary .....</b>                                 | <b>□□□□</b>     |

## List of Abbreviations

| <b>Abb.</b>        | <b>Full term</b>                         |
|--------------------|------------------------------------------|
| <b>ACA</b>         | Anterior cerebral artery                 |
| <b>ACE-I</b>       | Angiotensin converting enzyme inhibitors |
| <b>ACT</b>         | Activated clotting time                  |
| <b>AE</b>          | Adverse events                           |
| <b>AHA</b>         | American Heart Association               |
| <b>ARBs</b>        | Angiotensin receptor blockers            |
| <b>ARIC</b>        | Atherosclerosis risk in communities      |
| <b>ATP</b>         | Adenine triphosphate                     |
| <b>BES</b>         | Balloon-expandable stent                 |
| <b>BP</b>          | Blood pressure                           |
| <b>CCA</b>         | Cervical carotid artery                  |
| <b>CIN</b>         | Contrast-induced nephropathy             |
| <b>D. Normal</b>   | Diameter of normal                       |
| <b>D. Stenosis</b> | Diameter of stenosis                     |
| <b>DBP</b>         | Diastolic blood pressure                 |
| <b>DSA</b>         | Digital subtraction angiography          |
| <b>ECA</b>         | External carotid artery                  |
| <b>ECST</b>        | European Carotid Surgery Trial           |
| <b>FLAIR</b>       | Fluid-Attenuated Inversion Recovery      |
| <b>GP</b>          | Glycoprotein                             |
| <b>ICAS</b>        | Intracranial arterial stenosis           |
| <b>ICA</b>         | Internal carotid artery                  |
| <b>ICAD</b>        | Intracranial arterial disease            |
| <b>ICH</b>         | Intracerebral hemorrhage                 |
| <b>IPH</b>         | Intra parenchymal hematoma               |
| <b>IQR</b>         | Interquartile range                      |
| <b>IV</b>          | Intravenous                              |
| <b>LA</b>          | Left atrium                              |
| <b>LAA</b>         | Left atrial appendage                    |

| <b>Abb.</b>     | <b>Full term</b>                                                                                    |
|-----------------|-----------------------------------------------------------------------------------------------------|
| <b>MCA</b>      | Middle cerebral artery                                                                              |
| <b>MFV</b>      | Mean Flow velocity                                                                                  |
| <b>MRA</b>      | Magnetic resonance angiography                                                                      |
| <b>mRS</b>      | Modified Rankin Scale                                                                               |
| <b>NASCET</b>   | North American Symptomatic Carotid Endarterectomy Trial                                             |
| <b>NIH</b>      | National Institutes of Health                                                                       |
| <b>NIHSS</b>    | National Institute of Health Stroke Scale                                                           |
| <b>NPO</b>      | Nothing per OS                                                                                      |
| <b>PCA</b>      | Posterior cerebral artery                                                                           |
| <b>PCCA</b>     | Posterior communicating cerebral artery                                                             |
| <b>Pcom A</b>   | Posterior communicating artery                                                                      |
| <b>PFO</b>      | Patent foramen ovale                                                                                |
| <b>PT</b>       | Prothrombin time                                                                                    |
| <b>PTA</b>      | Percutaneous transluminal angioplasty                                                               |
| <b>PTAS</b>     | Percutaneous transluminal angioplasty and stent                                                     |
| <b>PTT</b>      | Partial thromboplastin time                                                                         |
| <b>RRR</b>      | Relative risk reduction                                                                             |
| <b>SAMMPRIS</b> | Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis |
| <b>SES</b>      | Self-expandable stent                                                                               |
| <b>SIAS</b>     | Symptomatic intracranial arterial stenosis                                                          |
| <b>TCD</b>      | Transcranial Doppler                                                                                |
| <b>TIA</b>      | Transient ischemic attack                                                                           |
| <b>TOF</b>      | Time-of-flight                                                                                      |
| <b>VZV</b>      | Varicella zoster virus                                                                              |
| <b>WASID</b>    | Warfarin-aspirin symptomatic intracranial disease                                                   |

## List of Figures

| <b>Figure</b> | <b>Title</b>                                                                                                                                                   | <b>Page</b> |
|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| <b>1</b>      | Endothelial dysfunction in atherosclerosis                                                                                                                     | 28          |
| <b>2</b>      | Fatty-streak formation in atherosclerosis                                                                                                                      | 28          |
| <b>3</b>      | Formation of an advanced, complicated lesion of atherosclerosis                                                                                                | 29          |
| <b>4</b>      | Unstable fibrous plaques in atherosclerosis                                                                                                                    | 29          |
| <b>5</b>      | Axial arterial anatomy of brain by MRA                                                                                                                         | 32          |
| <b>6</b>      | Intracranial CT angiogram in a patient with bilateral common carotid occlusion                                                                                 | 34          |
| <b>7</b>      | A 47-year-old female patient presented with right middle cerebral artery territory stroke                                                                      | 38          |
| <b>8</b>      | Lateral carotid angiogram shows that the cervical carotid artery is narrowed but it has a smooth outline, The supraclinoid internal carotid artery is occluded | 38          |
| <b>9</b>      | Angiographic methods for measurement of carotid stenosis                                                                                                       | 40          |
| <b>10</b>     | WASID methods                                                                                                                                                  | 41          |
| <b>11</b>     | Wingspan stent                                                                                                                                                 | 60          |
| <b>12</b>     | Balloon expandable stent                                                                                                                                       | 63          |
| <b>13</b>     | Self-expandable stent                                                                                                                                          | 63          |
| <b>14</b>     | Diagnostic phase of our patient                                                                                                                                | 76          |
| <b>15</b>     | Final image after stenting                                                                                                                                     | 79          |
| <b>16</b>     | MFV of both groups                                                                                                                                             | 107         |
| <b>17</b>     | Percent of stenosis among both groups                                                                                                                          | 109         |
| <b>18</b>     | Follow up after 6 months                                                                                                                                       | 111         |
| <b>19</b>     | Case presentation (1)                                                                                                                                          | 122         |
| <b>20</b>     | Case presentation (2)                                                                                                                                          | 123         |
| <b>21</b>     | Case presentation (3)                                                                                                                                          | 124         |

## List of Tables

| <b>Table</b> | <b>Title</b>                                                                 | <b>Page</b> |
|--------------|------------------------------------------------------------------------------|-------------|
| <b>1</b>     | Risk factor modification treatment goals                                     | 42          |
| <b>2</b>     | Age and sex characteristics of all cases                                     | 83          |
| <b>3</b>     | Distribution and stratification of the risk factors of intervention group    | 84          |
| <b>4</b>     | Radiological findings among intervention group                               | 85          |
| <b>5</b>     | MFV before and after intervention                                            | 86          |
| <b>6</b>     | Percent of stenosis before and after intervention according to Zaho Criteria | 87          |
| <b>7</b>     | DSA finding among intervention group                                         | 88          |
| <b>8</b>     | Operative characteristics among intervention group                           | 89          |
| <b>9</b>     | Postoperative characteristic data among intervention group                   | 90          |
| <b>10</b>    | NIHSS at baseline, three and six months among intervention group             | 92          |
| <b>11</b>    | Change of NIHSS at three and six months among intervention group             | 92          |
| <b>12</b>    | The mean of NIHSS at baseline, three and six months among intervention group | 92          |
| <b>13</b>    | Follow up after 6 months of interventions                                    | 93          |
| <b>14</b>    | mRS data at baseline, three and six months                                   | 95          |
| <b>15</b>    | Change of mRS at three and six months                                        | 95          |
| <b>16</b>    | Age and sex characteristics of medical cases                                 | 96          |
| <b>17</b>    | Distribution and stratification of the risk factors of medical group         | 97          |
| <b>18</b>    | Radiological findings among medical group                                    | 98          |
| <b>19</b>    | MFV before and after treatment                                               | 99          |

| <b>Table</b> | <b>Title</b>                                                                                                | <b>Page</b> |
|--------------|-------------------------------------------------------------------------------------------------------------|-------------|
| <b>20</b>    | Percent of stenosis before and after treatment                                                              | 100         |
| <b>21</b>    | NIHSS at baseline, three and six months among medical group                                                 | 101         |
| <b>22</b>    | The mean of NIHSS at baseline, three and six months among medical group                                     | 101         |
| <b>23</b>    | Change of NIHSS at three and six months among medical group                                                 | 101         |
| <b>24</b>    | Follow up after 6 months of medical group                                                                   | 102         |
| <b>25</b>    | mRS data at baseline, three and six months                                                                  | 103         |
| <b>26</b>    | Change of mRS at three and six months                                                                       | 103         |
| <b>27</b>    | Comparison of demographic data between the two study groups                                                 | 104         |
| <b>28</b>    | Comparison of risk factors between the two study groups                                                     | 105         |
| <b>29</b>    | Radiological data among both groups                                                                         | 105         |
| <b>30</b>    | MFV of both groups                                                                                          | 106         |
| <b>31</b>    | Percent of stenosis among both groups                                                                       | 108         |
| <b>32</b>    | Change of percent of stenosis                                                                               | 109         |
| <b>33</b>    | Follow up after 6 months in both groups                                                                     | 111         |
| <b>34</b>    | NIHSS at baseline, three and six months of both groups                                                      | 113         |
| <b>35</b>    | Change of NIHSS at three and six months of both groups                                                      | 113         |
| <b>36</b>    | MRS at baseline, three and six months of both groups                                                        | 115         |
| <b>37</b>    | MRS changes from the base line value to three months and six months follow up visit in the two study groups | 115         |

| <b>Table</b> | <b>Title</b>                                                                    | <b>Page</b> |
|--------------|---------------------------------------------------------------------------------|-------------|
| <b>38</b>    | Percent of stenosis pre and post stenting of intervention group                 | 116         |
| <b>39</b>    | Comparison between NIHSS at baseline and after three months after stenting      | 117         |
| <b>40</b>    | Comparison between NIHSS at 3 months and six months after stenting              | 117         |
| <b>41</b>    | Comparison between MRS at baseline and after three months after stenting        | 118         |
| <b>42</b>    | Comparison between MRS at three and six months after stenting                   | 118         |
| <b>43</b>    | Percent of stenosis pre and post stenting of medical group                      | 119         |
| <b>44</b>    | Comparison between NIHSS at baseline and after three months among medical group | 120         |
| <b>45</b>    | Comparison between NIHSS at three and six months among medical treatment        | 120         |
| <b>46</b>    | Comparison between MRS at baseline and after three months among medical group   | 121         |
| <b>47</b>    | Comparison between MRS at three and six months among medical group              | 121         |

# **Endovascular Management of Medically Refractory Intracranial Arterial Stenosis**

## **Abstract**

**Background:** Atherosclerotic intracranial arterial stenosis (ICAS) is one of the most common causes of stroke worldwide and is associated with a high risk of recurrent stroke. Patients with a recent transient ischemic attack (TIA) or stroke and severe stenosis (70 to 99% of the diameter of a major intracranial artery) are at particularly high risk for recurrent stroke in the territory of the stenotic artery (approximately 23% at 1 year) despite treatment with aspirin and standard management of vascular risk factors. Therefore, alternative therapies are urgently needed for these patients.

**Objective:** Our study aimed to determine the efficacy and safety of angioplasty with stenting in medically refractory intracranial arterial stenosis.

**Methodology:** The current study is a randomized prospective single center study carried out during the period from June 2016 to June 2018 at the Neuroendovascular Unit of El Mataria Teaching Hospital after obtaining an informed consent. Fifty patients were enrolled, randomized 1:1 and underwent twenty five stenting procedures and twenty five take medical treatment. The patients had been recruited from inpatient El Mataria Teaching Hospital admission and outpatient clinics.

**Results:** Success rate in our study was 96 % where only one patient failed to deployment of stent due to tortuosity of Vessels. Restenosis occurred in one patient after stenting and complete occlusion occurred in one patient also so the percent of restenosis was 8%.

**Conclusion:** Our study concluded that intracranial arterial stenting and best medical treatment superior in efficacy and safety than best medical treatment without stenting.

---

**Keywords:** Endovascular, Intracranial Arterial Stenosis

## Introduction

Stroke is a leading cause of death globally. Patients surviving a stroke or transient ischemic attack (TIA) are at an increased risk for subsequent strokes. Without secondary prevention measures, patients after stroke or TIA face an annual risk of 4-16% of developing serious vascular events **(Zhang et al., 2015)**.

Atherosclerotic intracranial arterial stenosis is one of the most common causes of stroke worldwide and is associated with a high risk of recurrent stroke. Patients with a recent transient ischemic attack (TIA) or stroke and severe stenosis (70 to 99% of the diameter of a major intracranial artery) are at high risk for recurrent stroke in the territory of the stenotic artery (approximately 23% at 1 year) despite treatment with aspirin and standard management of vascular risk factors. Therefore, alternative therapies are urgently needed for these patients **(Marc et al., 2011)**.

The pathophysiology of ischemic stroke secondary to intracranial arterial stenosis involves multiple mechanisms. Intracranial arterial stenosis may incite downstream ischemia in a specific arterial territory due to hypoperfusion, in situ thrombosis, artery-to-artery emboli,

perforator vessel occlusion by the atherosclerotic plaque, or combined mechanisms. There is an interrelated and complementary occurrence of hypoperfusion and embolism. Reduced blood perfusion distal to high-grade stenosis limits the ability of emboli from the stenosis to be washed out of the cerebral circulation and therefore may accumulate in the lowest perfusion pressure regions. Investigations using MRI and transcranial Doppler studies have corroborated this hypothesis and have suggested additional mechanisms in which stenosis and embolism act synergistically to produce ischemia **(Nestor, 2013)**.

Despite aggressive medical therapy, the risk of recurrent stroke in patients with symptomatic intracranial arterial disease (ICAD) is as high as 15% per year. In patients with severe stenosis (>70%) and in certain high-risk groups, the risk of recurrent stroke has been reported to be as high as 25% per year **(Gonzalez et al., 2013)**.

Successful management of patients with ICAD requires an intervention that is safe, effective, and has minimal complications. Medical treatment can reduce the risk of ischemic stroke due to thromboembolic events, but it does not reduce the risk of ICAD progression and the associated pathophysiologic components of hypoperfusion and poor collateral circulation **(Taylor et al., 2014)**.

Current primary prevention strategies include a combination of life style modification (smoking cessation, dietary intervention, weight loss and exercise), antihypertensive medications, antithrombotic therapy and statins. Recommended secondary prevention includes a combination of medical therapy and revascularization. Tremendous advances were made in cerebral revascularization techniques in recent years, which include percutaneous transluminal angioplasty (PTA) alone and PTA with stenting (PTAS) using balloon-mounted coronary stents **(Muthanna & Raghavan, 2012)**.

Angioplasty has traditionally been used for the treatment of intracranial stenosis, primarily for intracranial stenosis refractory to medical therapy. However, since no stent is specifically designed for intracranial arteries, treatment is usually completed with balloon angioplasty alone **(Takashi et al., 2014)**.

Balloon angioplasty has several advantages over bypass surgery in treating the stenotic lesion of the middle cerebral artery (MCA). First, the ability to access to the stenotic lesion and start angioplasty more promptly after neurological deterioration of the patient compared to bypass surgery. Second, endovascular treatment could be performed without induction of general anesthesia and

considered to be less invasive than open surgery. Third microembolism is thought to be one of the mechanisms of cerebral ischemia in intracranial stenosis, so we consider angioplasty of the lesion may be more essential than bypass surgery in treating the stenotic lesion (**Hideo et al., 2015**).

Despite the low one year stroke rates following intracranial angioplasty, restenosis remains a possible weakness of primary angioplasty. Symptomatic and angiographic restenosis occur at 6 months in approximately 5–30% of patients treated with angioplasty alone. The re-angioplasty rate was in excess of 20% in the most recent study in which sub-maximal technique was rigorously employed (**Dumont et al., 2012**).

Stenting was developed in response to the need for better outcomes after angioplasty and was proven to be effective by reducing the occurrence of plaque dislodgement, intimal dissection, elastic recoil of the vessel wall, and early and late restenosis (**Farooq et al., 2014**).

Stenting has been a popular treatment for intracranial stenosis, particularly with the advent of the Wingspan® Stent System is an endovascular tool. As with the placement of any bare metal stent, intracranial stents require dual antiplatelet therapy during the stent

endothelialization period. So, treating the areas of intracranial stenosis with angioplasty and stenting. Through improving vessel caliber in the stenotic segment, is more beneficial than medical therapy alone. Theoretically, angioplasty and stenting should increase blood flow and decrease the incidence of watershed infarcts secondary to chronic cerebral ischemia due to hypoperfusion. Early reports of stenting for ICAD showed promise to this end. Bare metal stents, balloon mounted (balloon-expandable) stents, and drug-eluting stents have been evaluated for this purpose **(Lee et al., 2013)**.

A joint position statement by major radiology and neuroradiology societies in October 2005, in alignment with the FDA indication, concluded that balloon angioplasty with or without stenting should be considered in patients who had failed medical therapy **(Aakriti et al., 2013)**.